Evidence map›Paper›PMID 37676628›Full record

ArticleImmunologic research2024

ANCA detection with solid phase chemiluminescence assay: diagnostic and severity association in vasculitis.

Mónica Renuncio-García, Vanesa Calvo-Río, Fabricio Benavides-Villanueva, Salma Al Fazazi, María Rodríguez-Vidriales, Clara Escagedo-Cagigas, Luis Martín-Penagos, Juan Irure-Ventura, Marcos López-Hoyos, Ricardo Blanco

Open access · hybridAbstract read
In one paragraph

Article in Immunologic research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Mónica Renuncio-GarcíaDepartment of Immunology, Marqués de Valdecilla University Hospital, Avda. Valdecilla S/N, 39008, Santander, Cantabria, Spain.
Vanesa Calvo-RíoImmunopathology Group, Marqués de Valdecilla University Hospital-IDIVAL, 39011, Santander, Spain.
Fabricio Benavides-VillanuevaDepartment of Rheumatology, Marqués de Valdecilla University Hospital, 39008, Santander, Cantabria, Spain.
Salma Al FazaziDepartment of Rheumatology, Puerta del Mar University Hospital, 11009, Cádiz, Andalucía, Spain.
María Rodríguez-VidrialesDepartment of Nephrology, Marqués de Valdecilla University Hospital, 39008, Santander, Cantabria, Spain.
Clara Escagedo-CagigasDepartment of Nephrology, Marqués de Valdecilla University Hospital, 39008, Santander, Cantabria, Spain.
Luis Martín-PenagosImmunopathology Group, Marqués de Valdecilla University Hospital-IDIVAL, 39011, Santander, Spain.
Juan Irure-VenturaDepartment of Immunology, Marqués de Valdecilla University Hospital, Avda. Valdecilla S/N, 39008, Santander, Cantabria, Spain.
Marcos López-HoyosDepartment of Immunology, Marqués de Valdecilla University Hospital, Avda. Valdecilla S/N, 39008, Santander, Cantabria, Spain. marcos.lopez@scsalud.es.ORCID 0000-0003-0562-427X
Ricardo BlancoImmunopathology Group, Marqués de Valdecilla University Hospital-IDIVAL, 39011, Santander, Spain.
Marqués de Valdecilla University Hospital · ESHospital Universitario Puerta del Mar · ESUniversidad de Cantabria · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

ANCA-associated vasculitis (AAV) comprises a group of necrotizing vasculitis that mainly affects small- and medium-sized vessels. Serum anti-neutrophil cytoplasmic antibodies (ANCA), mainly anti-myeloperoxidase (anti-MPO) and anti-proteinase 3 (anti-PR3), levels may correlate to severity, prognosis, and recurrence of the disease. A retrospective analysis of 101 patients with MPO-positive and 54 PR3-positive vasculitis was performed, using laboratory established cut-off value, measured by chemiluminescence. Furthermore, data of renal disease and pulmonary involvement were collected at vasculitis diagnosis, as well as the progress, requiring dialysis, transplant, or mortality. For anti-MPO antibodies with a diagnosis of vasculitis (n = 77), an area under the curve (AUC) was calculated (AUC = 0.8084), and a cut-off point of 41.5 IU/ml was determined. There were significant differences in anti-MPO levels between patients with renal or pulmonary dysfunction (n = 65) versus those without them (n = 36) (p = 0.0003), and a cut-off threshold of 60 IU/ml was established. For anti-PR3 antibodies with a diagnosis of vasculitis (n = 44), an area under the curve (AUC) was calculated (AUC = 0.7318), and a cut-off point of 20.5 IU/ml was determined. Significant differences in anti-PR3 levels were observed between those patients with renal or pulmonary dysfunction (n = 30) and those without them (n = 24) (p = 0.0048), and a cut-off threshold of 41.5 IU/ml was established. No significant differences between those patients who had a worse disease progression and those who did not were found for anti-MPO and anti-PR3. Anti-MPO and anti-PR3 levels at the moment of vasculitis diagnosis are related with disease severity but not with disease outcome or vasculitis recurrence.

Indexed as

Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisGranulomatosis with PolyangiitisAntibodies, Antineutrophil CytoplasmicHumansLuminescenceMyeloblastinPeroxidaseRetrospective StudiesAntibodies, Antineutrophil CytoplasmicMyeloblastinPeroxidaseANCA-associated vasculitisAntibody titerAnti-MPO and anti-proteinase 3Eosinophilic granulomatosis with polyangiitisGranulomatosis with polyangiitisMicroscopic polyangiitisPrognosisSeveritySingle-organ ANCA vasculitis

Identifiers

PMID37676628
PMCPMC10810966
OpenAlexW4386502012

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.